drugset
drugset / Trial / NCT03615196

Study of the Safety of USB005 in Healthy Volunteers

NCT03615196 ↗

Phase 1 Completed 32 enrolled US Biotest, Inc. United States Department of Defense · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

This study will evaluate the safety, tolerability and pharmacokinetics of USB005 (aclerastide) Ophthalmic Solution.

Timeline

Start
2018-07-25
Primary completion
2018-11-08
Completion
2019-04-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aclerastide Protein / enzyme biologic 0.03 % Topical
Subject Aclerastide Protein / enzyme biologic 0.1 % Topical
Subject Aclerastide Protein / enzyme biologic 0.3 % Topical
Subject Aclerastide Protein / enzyme biologic 0.45 % Topical

Indications

No indication recorded.